Hi John
In answer to your question about Glivec holidays, there are a few studies on adherence and its relationship to molecular response. Perhaps the best is the study by David Marin (Hammersmith) et al, which was published in the American Journal of Clinical Oncology in September 2010 (and probably elsewhere). I can't post a link but if you put "cml adherence" into Google it will come up (hit no 3 in my search). In a nutshell, it seems to establish that adherence to therapy is a, perhaps the, major factor in achieving the best responses to TKI therapy: the level of adherence at which this factor seems to begin to show itself is actually quite high. Below adherence of 90% there is a statistically relevant correlation, and below 80%, for patients on the study, none achieved MMR. Bottom line is - the better the adherence, the better the outcome.
On the stop trial issue, I think you refer to the ongoing French STIM trial (Stop Imatinib) which at current levels of follow up (2 years I think) seems to show that for a proportion of patients in long term CMR, it may be possible to stop imatinib long term. It does also so far seem to show that those in that trial who lose their CMR after stopping imatinib regain it when put back on the drug. However, those running the study have made it very clear that only those in long term CMR are eligible to enrol in the trial (which would include you, if you were in France) and that stopping therapy should only be done as part of a clinical trial, with close monitoring. There are plans for a similar trial in the UK but that has been approved yet as far as I know.
Aside from this, I would agree with Sandy that any Glivec or other TKI "holiday" is something I would only do having discussed it in detail with my consultant. People do do it for various reasons, but I think it also depends on your current response level, personal circumstances etc.
Rgds
Richard